Can a patient experiencing opioid withdrawal be given lorazepam (Ativan)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, lorazepam (Ativan) can be given to patients experiencing opioid withdrawal and is explicitly recommended as part of symptomatic treatment.

Benzodiazepines like lorazepam are specifically endorsed in current guidelines for managing opioid withdrawal symptoms, particularly for anxiety, agitation, and muscle cramps. 1

Clinical Rationale

The 2020 American College of Emergency Physicians guidelines explicitly state that benzodiazepines may help reduce catecholamine release during withdrawal and help alleviate muscle cramps as well as anxiety 1. This represents a recognized component of nonopioid treatment strategies for opioid withdrawal.

Mechanism of Benefit

Lorazepam addresses several key withdrawal symptoms:

  • Anxiety and agitation - Direct anxiolytic effect
  • Muscle cramps and spasms - Muscle relaxant properties
  • Catecholamine surge - Reduces sympathetic hyperactivity during withdrawal 1

Treatment Framework

Lorazepam should be used as adjunctive symptomatic therapy, not as primary treatment for opioid withdrawal:

Primary Treatment Hierarchy

  1. Buprenorphine (most effective, reduces mortality) 1
  2. Methadone (equally effective but less commonly used in ED settings) 1
  3. Alpha-2 agonists (clonidine, lofexidine) for moderate symptoms 1

Adjunctive Medications (Including Lorazepam)

  • Benzodiazepines for anxiety, agitation, muscle cramps
  • Antiemetics (promethazine, ondansetron) for nausea/vomiting
  • Antidiarrheals (loperamide) for diarrhea
  • NSAIDs (ibuprofen) for myalgias 1, 2

Critical Safety Considerations

Respiratory Depression Risk

The FDA label for Ativan carries a black box warning about concomitant use with opioids 3. However, this applies to patients actively using opioids, not those in withdrawal:

  • During active withdrawal (when opioids are being eliminated): Lorazepam is safer because opioid levels are declining
  • Risk increases if: Patient relapses and uses opioids while benzodiazepines are still active
  • Monitor closely: Respiratory rate, sedation level, oxygen saturation

Dosing Approach

Use conservative dosing to avoid oversedation:

  • Start with lorazepam 0.5-1 mg PO/IV as needed
  • Reassess every 1-2 hours
  • Avoid scheduled dosing unless severe agitation persists
  • Document withdrawal severity (use COWS score) 1

Common Pitfalls to Avoid

  1. Using benzodiazepines as monotherapy: Always prioritize buprenorphine or methadone for definitive treatment, as these reduce mortality 2

  2. Missing precipitated withdrawal: If patient recently used long-acting opioids (methadone, extended-release formulations), ensure adequate time has passed before starting buprenorphine (>24-72 hours) 1

  3. Overlooking substance use disorder risk: While lorazepam helps acute symptoms, patients with opioid use disorder have elevated risk for benzodiazepine misuse 3. Limit quantities and duration.

  4. Confusing withdrawal with intoxication: Opioid withdrawal causes agitation and sympathetic hyperactivity (tachycardia, hypertension, mydriasis), not sedation 1

Evidence Quality Note

The guideline recommendations for benzodiazepines in opioid withdrawal are based on clinical consensus and physiological rationale rather than high-quality comparative trials 1. The strongest evidence supports buprenorphine and methadone as primary treatments, with benzodiazepines playing a supportive role for specific symptoms.

Bottom line: Lorazepam is appropriate and guideline-supported for symptomatic management of opioid withdrawal, but should complement—not replace—opioid agonist therapy (buprenorphine or methadone) which reduces mortality and improves treatment retention.

References

Related Questions

Are opioid withdrawal symptoms life‑threatening?
In a patient with cirrhosis experiencing alcohol withdrawal, should lorazepam (Ativan) or diazepam (Valium) be used?
What are the benefits of initiating methadone maintenance in a hospitalized patient with chronic injection opioid use compared to the risk of respiratory depression?
How should buprenorphine‑naloxone (Suboxone) be initiated and managed in primary care for an adult patient with opioid use disorder who is not acutely intoxicated, does not have severe respiratory depression, and does not have uncontrolled severe pain?
Is it safe to consume alcohol while taking benzodiazepines such as lorazepam 1 mg twice daily, clonazepam 0.5 mg at bedtime, or diazepam 5 mg three times daily?
What fasting serum C‑terminal telopeptide (CTX) value indicates adequate bone resorption suppression in a postmenopausal woman taking alendronate?
What do black longitudinal melanonychia (black lines) on the fingernails indicate?
What is the recommended vitamin D dosing for children with vitamin D deficiency?
Should a thyroid‑stimulating hormone level of 5.13 mIU/L be treated with levothyroxine?
In a patient with a negative Bravo pH study for gastroesophageal reflux disease who is taking gabapentin and experiencing increased viscous saliva secretions and cough, what foods or nutraceuticals could help alleviate these symptoms?
For a patient with chronic cough, negative Bravo pH monitoring, normal pulmonary function tests, completed speech‑therapy, on gabapentin (causing thick saliva), and concerned about prebiotic use, what does a negative barium swallow indicate and how should the management plan be adjusted?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.